| scholarly article | Q13442814 |
| P2093 | author name string | Yang Zhang | |
| Jing Wang | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer | Q24604601 | ||
| MicroRNAs: target recognition and regulatory functions | Q24609584 | ||
| Pharmacogenomics knowledge for personalized medicine | Q24623166 | ||
| Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers | Q24625794 | ||
| MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2) | Q24630209 | ||
| Pharmacologic resistance in colorectal cancer: a review | Q26769850 | ||
| Cancer Metabolism and Drug Resistance | Q26782042 | ||
| Self-consumption: the interplay of autophagy and apoptosis | Q26828473 | ||
| Cancer stem cells and drug resistance: the potential of nanomedicine | Q26998993 | ||
| MicroRNA biogenesis pathways in cancer | Q27013841 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets | Q27860792 | ||
| microRNA Therapeutics in Cancer - An Emerging Concept | Q28068855 | ||
| Lessons from hereditary colorectal cancer | Q28131788 | ||
| Fluorinated pyrimidines, a new class of tumour-inhibitory compounds | Q28214124 | ||
| Regulation of microRNA biogenesis | Q28243976 | ||
| Cancer drug resistance: an evolving paradigm | Q29616694 | ||
| Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status | Q29619648 | ||
| Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale | Q33366660 | ||
| Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial | Q33417569 | ||
| Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells | Q33895297 | ||
| MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression | Q33917538 | ||
| miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase | Q34013539 | ||
| MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer | Q34282551 | ||
| Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. | Q34328725 | ||
| Evolution of colorectal cancer: change of pace and change of direction. | Q34622521 | ||
| miR-34 - a microRNA replacement therapy is headed to the clinic | Q34640230 | ||
| FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial | Q34663697 | ||
| A review of the evolution of systemic chemotherapy in the management of colorectal cancer | Q34667476 | ||
| Emerging concepts in colorectal neoplasia | Q34800070 | ||
| MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. | Q35008686 | ||
| Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy | Q35039281 | ||
| Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. | Q35085558 | ||
| MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer | Q35172941 | ||
| MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. | Q35672735 | ||
| MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer | Q35859038 | ||
| MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer | Q36022236 | ||
| High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease | Q36051517 | ||
| The microcosmos of cancer | Q36432986 | ||
| MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers | Q36906199 | ||
| miR-139-5p Inhibits the Epithelial-Mesenchymal Transition and Enhances the Chemotherapeutic Sensitivity of Colorectal Cancer Cells by Downregulating BCL2 | Q36950630 | ||
| miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells. | Q36962611 | ||
| Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis. | Q37246966 | ||
| Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody | Q37605237 | ||
| The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance | Q38037329 | ||
| A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia | Q38061861 | ||
| Targeting cancer stem cells to suppress acquired chemotherapy resistance | Q38149736 | ||
| Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. | Q38172752 | ||
| MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications | Q38174308 | ||
| Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma | Q38207042 | ||
| Poised epigenetic states and acquired drug resistance in cancer | Q38254072 | ||
| Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. | Q38384387 | ||
| Transforming Growth Factor β Mediates Drug Resistance by Regulating the Expression of Pyruvate Dehydrogenase Kinase 4 in Colorectal Cancer | Q38762901 | ||
| Inhibition of lactate dehydrogenase A by microRNA-34a resensitizes colon cancer cells to 5-fluorouracil | Q38946267 | ||
| Overexpression of microRNA-122 re-sensitizes 5-FU-resistant colon cancer cells to 5-FU through the inhibition of PKM2 in vitro and in vivo | Q38988213 | ||
| MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17. | Q39335270 | ||
| miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2. | Q39335411 | ||
| miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells | Q39436512 | ||
| MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. | Q39467884 | ||
| Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML. | Q39475165 | ||
| Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells | Q42009448 | ||
| miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer | Q42051478 | ||
| Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia | Q42615624 | ||
| Isolation of a tumor factor responsible for angiogenesis | Q42835506 | ||
| miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance | Q42921031 | ||
| Oxaliplatin | Q44751137 | ||
| Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 | Q56679480 | ||
| Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase acti | Q70218958 | ||
| miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression | Q83483248 | ||
| Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells | Q84145725 | ||
| MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells | Q86111152 | ||
| MicroRNA-195 chemosensitizes colon cancer cells to the chemotherapeutic drug doxorubicin by targeting the first binding site of BCL2L2 mRNA | Q86485144 | ||
| P433 | issue | 8 | |
| P921 | main subject | colorectal cancer | Q188874 |
| microRNA | Q310899 | ||
| P304 | page(s) | 929-938 | |
| P577 | publication date | 2017-07-01 | |
| P1433 | published in | Biological Chemistry | Q4914948 |
| P1476 | title | MicroRNAs are important regulators of drug resistance in colorectal cancer | |
| P478 | volume | 398 |
| Q90724866 | Clinical Theragnostic Relationship between Drug-Resistance Specific miRNA Expressions, Chemotherapeutic Resistance, and Sensitivity in Breast Cancer: A Systematic Review and Meta-Analysis |
| Q83600815 | Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway |
| Q89966162 | High-Throughput Transcriptome Profiling in Drug and Biomarker Discovery |
| Q90630048 | Inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway |
| Q91893378 | MiR-6803-5p Promotes Cancer Cell Proliferation and Invasion via PTPRO/NF-κB Axis in Colorectal Cancer |
| Q57156048 | Non-coding RNA in drug resistance of hepatocellular carcinoma |
| Q89915740 | SEZ6L2 knockdown impairs tumour growth by promoting caspase-dependent apoptosis in colorectal cancer |
| Q90344722 | Single Cell Transcriptome in Colorectal Cancer-Current Updates on Its Application in Metastasis, Chemoresistance and the Roles of Circulating Tumor Cells |
| Q64229129 | The Developing Story of Predictive Biomarkers in Colorectal Cancer |
| Q64097710 | miR-21-mediated regulation of 15-hydroxyprostaglandin dehydrogenase in colon cancer |
| Q58799032 | miRNAs and lncRNAs as Predictive Biomarkers of Response to FOLFOX Therapy in Colorectal Cancer |
Search more.